High Free Cash Flow Stocks
ALKS is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
ALKERMES PLC (ALKS) Stock Price & Overview
NASDAQ:ALKS • IE00B56GVS15
Current stock price
33.71 USD
-0.43 (-1.26%)
At close:
33.66 USD
-0.05 (-0.15%)
After Hours:
The current stock price of ALKS is 33.71 USD. Today ALKS is down by -1.26%. In the past month the price decreased by -4.67%. In the past year, price increased by 6.07%.
ALKS Key Statistics
52-Week Range25.165 - 36.48
Current ALKS stock price positioned within its 52-week range.
1-Month Range32.47 - 36.48
Current ALKS stock price positioned within its 1-month range.
- Market Cap
- 5.604B
- P/E
- 19.60
- Fwd P/E
- N/A
- EPS (TTM)
- 1.72
- Dividend Yield
- N/A
ALKS Stock Performance
Today
-1.26%
1 Week
-0.09%
1 Month
-4.67%
3 Months
-0.53%
Longer-term
6 Months +9.80%
1 Year +6.07%
2 Years +37.37%
3 Years +18.07%
5 Years +53.19%
10 Years -15.20%
ALKS Stock Chart
ALKS Stock Screens
ALKS currently appears in the following ChartMill screener lists.
High Quality Stocks
ALKS is part of our High Quality Stocks screen, meaning it meets strict criteria for profitability, capital efficiency, and long-term growth consistency.
Breakout Setups
ALKS appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
Most Shorted Stocks
ALKS is part of our most shorted stocks screen list, indicating it has a high short interest.
ALKS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALKS. When comparing the yearly performance of all stocks, ALKS turns out to be only a medium performer in the overall market: it outperformed 46.87% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ALKS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALKS. ALKS gets an excellent profitability rating and is at the same time showing great financial health properties.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ALKS Earnings
On February 25, 2026 ALKS reported an EPS of 0.29 and a revenue of 384.55M. The company missed EPS expectations (-16.95% surprise) and missed revenue expectations (-1.55% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.29
Revenue Reported384.547M
EPS Surprise -16.95%
Revenue Surprise -1.55%
ALKS Forecast & Estimates
24 analysts have analysed ALKS and the average price target is 44.46 USD. This implies a price increase of 31.89% is expected in the next year compared to the current price of 33.71.
For the next year, analysts expect an EPS growth of -138.6% and a revenue growth 22.19% for ALKS
Analysts
Analysts81.67
Price Target44.46 (31.89%)
EPS Next Y-138.6%
Revenue Next Year22.19%
ALKS Index Membership
ALKS is currently included in the following stock indexes tracked on ChartMill.
ALKS Financial Highlights
Over the last trailing twelve months ALKS reported a non-GAAP Earnings per Share(EPS) of 1.72. The EPS decreased by -40.76% compared to the year before.
Income Statements
Revenue(TTM)1.48B
Net Income(TTM)241.66M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.37% | ||
| ROA | 9.72% | ||
| ROE | 13.28% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-72.38%
Sales Q2Q%-10.57%
EPS 1Y (TTM)-40.76%
Revenue 1Y (TTM)-5.25%
ALKS Ownership
Ownership
Inst Owners109.71%
Shares166.25M
Float163.19M
Ins Owners1.59%
Short Float %12.06%
Short Ratio8.32
ALKS Industry Overview
ALKS operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
37/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
23%
Outperformed 23% of sub-industries
3 Month Rank
21%
Outperformed 21% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.7%
- Average Operating Margin
- 25.9%
- Average P/E
- 38.1
- Average Fwd P/E
- 30.1
- Average Debt/Equity
- 0.0
ALKS Latest News, Press Relases and Analysis
13 hours ago - By: Chartmill
ALKS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALKS
Company Profile
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,050 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Company Info
IPO: 1991-07-16
ALKERMES PLC
Connaught House, 1 Burlington Road, Dublin 4
DUBLIN DUBLIN DUBLIN 4 IE
CEO: Richard F. Pops
Employees: 2050
Phone: 35317728000
ALKERMES PLC / ALKS FAQ
What does ALKS do?
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,050 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
What is the stock price of ALKERMES PLC today?
The current stock price of ALKS is 33.71 USD. The price decreased by -1.26% in the last trading session.
Does ALKS stock pay dividends?
ALKS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALKS stock?
ALKS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for ALKS stock?
The PE ratio for ALKERMES PLC (ALKS) is 19.6. This is based on the reported non-GAAP earnings per share of 1.72 and the current share price of 33.71 USD.
What is ALKERMES PLC worth?
ALKERMES PLC (ALKS) has a market capitalization of 5.60B USD. This makes ALKS a Mid Cap stock.
Can you provide the ownership details for ALKS stock?
You can find the ownership structure of ALKERMES PLC (ALKS) on the Ownership tab.